SciELO - Scientific Electronic Library Online

 
vol.26 issue3Incorporation of cortical intercalary bone allografts: Experimental study on rabbitsTwelve years of the Infant Oral Care Program (PADI) in Navarra (1991-2002): Utilisation and health indicators author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Anales del Sistema Sanitario de Navarra

Print version ISSN 1137-6627

Abstract

PUJOL, A. et al. Clinical complications in a series of patients with anticardiolipin antibodies. Anales Sis San Navarra [online]. 2003, vol.26, n.3, pp.365-372. ISSN 1137-6627.

An analysis was made of clinical complications, determined with objective methods, in 68 patients at the University Clinic of Navarra with the clinical suspicion of antiphospholipid syndrome (APS) and presence of anticardiolipin antibodies (ACA). Patients with IgG higher than 23 GPL were considered for the study. The most prevalent pathology was thrombosis: venous thrombosis (42.6%) and arterial thrombosis (22%). Other complications were abortions (23.8% of the 42 women) and thrombocytopenia (12.1%). With respect to the localisation of venous thrombosis, predominance corresponded to lower extremities (51.7%), followed by superficial thrombophlebitis (27.5%) and pulmonary thromboembolism (20.6%). Among the arterial complications, the most frequent were cerebrovascular disease (86.6 %) and coronary disease (13.4%). There was no correlation between the presence of high values of ACA and the prevalence or severity of clinical manifestations. In the series of patients with ACA IgG23 GPL, we appreciated a high percentage of venous and arterial thrombosis detected with objective methods. The presence of ACA constitutes a prothrombotic risk factor.

Keywords : Antiphospolipid syndrome; Anticardiolipin antibodies; Venous thrombosis; Arterial thrombosis; Lupus anticoagulant.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License